C De Block
Overview
Explore the profile of C De Block including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
273
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Van Mieghem E, De Block C, De Herdt C
Pituitary
. 2023 Dec;
27(1):23-32.
PMID: 38151529
Isolated adrenocorticotropic hormone deficiency (IAD) is considered to be a rare disease. Due to the nonspecific clinical presentation, precise data on the prevalence and incidence are lacking. In this systematic...
2.
Hartman V, Op de Beeck B, Chapelle T, Bracke B, Ysebaert D, De Block C, et al.
Acta Chir Belg
. 2019 Apr;
120(4):257-264.
PMID: 31008690
The aim of this study is to evaluate the use of pancreatic volumetric assessment to predict exocrine and endocrine insufficiency after pancreaticoduodenectomy. Thirty-seven patients who underwent pancreaticoduodenectomy were included in...
3.
Hermans M, De Bacquer D, De Block C, Truyers C, Vankeirsbilck A, De Backer G
Rev Med Liege
. 2014 Jun;
69(4):200-9.
PMID: 24923100
Cardiovascular disease (CVD) is the main cause of premature mortality in Europe. The burden of CVD could be reduced by controlling the major modifiable CVD risk factors (dyslipidaemia, arterial hypertension,...
4.
Gorus F, Balti E, Vermeulen I, DeMeester S, van Dalem A, Costa O, et al.
Clin Exp Immunol
. 2012 Dec;
171(1):82-90.
PMID: 23199327
In first-degree relatives of type 1 diabetic patients, we investigated whether diabetes risk assessment solely based on insulinoma antigen 2 (IA-2) and zinc transporter 8 (ZnT8) antibody status (IA-2A, respectively,...
5.
Keymeulen B, Walter M, Mathieu C, Kaufman L, Gorus F, Hilbrands R, et al.
Diabetologia
. 2010 Mar;
53(4):614-23.
PMID: 20225393
Aims/hypothesis: The aim of the study was to examine the 48 month outcome of treating recent-onset type 1 diabetic patients for 6 days with humanised CD3-antibody, ChAglyCD3. Methods: Eighty patients,...
6.
Van den Driessche A, Eenkhoorn V, Van Gaal L, De Block C
Neth J Med
. 2009 Dec;
67(11):376-87.
PMID: 20009114
Type 1 diabetes mellitus (T1DM) results from autoimmune destruction of insulin-producing beta cells and is characterised by the presence of insulitis and &and beta-cell autoantibodies. Up to one third of...
7.
De Block C, Paquot N, Daoudi N, Ballaux D, Van Gaal L, Scheen A
Rev Med Liege
. 2009 Nov;
64(10):488-95.
PMID: 19911661
This is a retrospective analysis of medical records in 4 Belgian diabetes centres of 3 cohorts of patients with type 2 diabetes, with data available, respectively, after 3 months <...
8.
Vandemeulebroucke E, Keymeulen B, Decochez K, Weets I, De Block C, Fery F, et al.
Diabetologia
. 2009 Nov;
53(1):36-44.
PMID: 19898832
Aims/hypothesis: The aim of the study was to investigate the use of hyperglycaemic clamp tests to identify individuals who will develop diabetes among insulinoma-associated protein-2 antibody (IA-2A)-positive first-degree relatives (IA-2A(+)...
9.
Vandemeulebroucke E, Gorus F, Decochez K, Weets I, Keymeulen B, De Block C, et al.
Diabetes Metab
. 2009 Aug;
35(4):319-27.
PMID: 19647467
Aims: We examined whether parenteral regular insulin can prevent diabetes in IA-2 antibody-positive (IA-2A+) relatives of type 1 diabetic patients, using a trial protocol that differed substantially from that of...
10.
Weets I, Rooman R, Coeckelberghs M, De Block C, Van Gaal L, Kaufman J, et al.
Diabetes Metab Res Rev
. 2007 Jul;
23(8):637-43.
PMID: 17631647
Background: The age at clinical onset of type 1 diabetes is decreasing. Preliminary Belgian data suggested that this anticipation occurred preferentially in boys. We investigated whether this gender-specific anticipation could...